Analyst Warns AI Hype Diverts Biomanufacturing Capital
A market analyst critiqued the current investment climate, arguing that hype around AI is cannibalizing capital that would otherwise go to biomanufacturing, diagnostics, and agricultural innovation. The commentary warns that underinvestment in these core areas could lead to future shortages.
- While overall U.S. healthcare venture funding grew from $20 billion in 2023 to $23 billion in 2024, nearly 30% of that 2024 capital went to AI-leveraging companies. Investment in AI-backed healthcare firms specifically saw a near-tripling in 2024, reaching $5.6 billion. - The capital allocation reflects a focus on valuation premiums, with AI-native biotechs raising funds at a median valuation of $78 million in 2024, almost double the $40 million median for the broader biopharma industry. - This investment shift coincides with significant capital needs in viral vector manufacturing, where a 10- to 100-fold increase in production capacity is required as gene therapies move beyond ultrarare indications. High-profile manufacturing and quality control issues remain a major hurdle; 74% of FDA Complete Response Letters between 2020 and 2024 cited such problems as the primary reason for rejection. - For Industry 4.0 applications, technologies like digital twins for bioprocess optimization face significant cost barriers to entry, despite their potential to reduce risks and accelerate timelines. The market for bioprocess digital twins is projected to grow at 18.7% annually to reach $6.17 billion by 2033, indicating a long-term investment cycle. - Some large pharmaceutical companies are opting to partner or acquire late-stage platforms rather than build complex internal cell therapy manufacturing capabilities. Takeda, for example, exited its cell therapy research in 2025, taking a $395 million impairment. - A parallel trend is occurring in agriculture, where the market for AI is expected to grow from $1.7 billion in 2023 to $4.7 billion by 2028. Investment is flowing into AI for crop protection discovery, disease detection, and precision application of herbicides.
